News Release

Researchers unlock secret of deadly brain cancer's 'immortality'

New therapeutic target identified in glioblastoma could be effective against a common immortality mechanism in one third of human cancers

Peer-Reviewed Publication

University of California - San Francisco

UC San Francisco researchers have discovered how a mutation in a gene regulator called the TERT promoter -- the third most common mutation among all human cancers and the most common mutation in the deadly brain cancer glioblastoma -- confers "immortality" on tumor cells, enabling the unchecked cell division that powers their aggressive growth.

The research, published September 10, 2018 in Cancer Cell, found that patient-derived glioblastoma cells with TERT promoter mutations depend on a particular form of a protein called GABP for their survival. GABP is critical to the workings of most cells, but the researchers discovered that the specific component of this protein that activates mutated TERT promoters, a subunit called GABP-ß1L, appears to be dispensable in normal cells: Eliminating this subunit using CRISPR-based gene editing dramatically slowed the growth of the human cancer cells in lab dishes and when they were transplanted into mice, but removing GABP-ß1L from healthy cells had no discernable effect.

"These findings suggest that the ß1L subunit is a promising new drug target for aggressive glioblastoma and potentially the many other cancers with TERT promoter mutations," said study senior author Joseph Costello, PhD, a leading UCSF neuro-oncology researcher.

Immortality is one of the key traits of cancer cells. In contrast to healthy cells, which are strictly limited in the number of times they are able to divide, cancer cells can go on dividing and multiplying forever, in many cases accumulating additional cancer-driving mutations as they go.

Normally, cellular life spans are set by structures called telomeres -- protective caps that sit at the ends of chromosomes like the aglets at the end of a shoelace. Telomeres shorten each time a cell divides, until eventually they are too short to protect the DNA any longer, a signal the cell has reached the end of its natural life span and should be retired like a balding car tire.

Tumor cells in most cancers get around this limitation by stealing the secret of immortality from long-lived stem cells, which can divide indefinitely thanks to a telomere-extending enzyme called telomerase, the discovery of which led to a Nobel prize shared by UCSF's Elizabeth Blackburn, PhD. Normally only stem cells are allowed to cheat death in this way, but scientists estimate that as many as 90 percent of human cancers have activated telomerase, many through mutations in TERT, one of the two genes that encodes the telomerase complex, which enable them to grow and spread unfettered by the limitations of normal cells.

Efforts to treat cancers with drugs that block telomerase have mostly proven too toxic to patients because they interfere with telomere maintenance in stem cells such as those needed to maintain healthy blood.

But recent research has suggested that more than 50 types of human cancers may be caused not by a defective TERT gene itself, but by mutations in the TERT promoter -- a region of DNA where protein complexes called transcription factors can influence when and how the TERT gene is activated. These mutations enable a transcription factor called GABP to bind to the TERT promoter and activate it, other studies had found, which was strange because in healthy cells GABP and TERT usually have nothing to do with one another.

"This was really intriguing to us," Costello said. "You can't create a drug to target a promoter itself, but if we could identify how GABP was binding to the mutated promoter in these cancers, we might have a remarkably powerful new drug target."

Costello's team, led by graduate students Andrew Mancini and Ana Xavier-Magalhaes, studied human glioblastoma cell lines and primary tumor cells derived from advanced-stage glioblastoma patients and showed that the cells' mutations create two adjacent sequences of DNA in the TERT promoter that make a perfect landing pad for a particular form of the GABP transcription factor complex containing four subunits, one of which was GABP-ß1L.

The researchers showed that this GABP-ß1L-containing form of GABP is required to activate TERT and drive cancer growth, but that it appears not to be essential for healthy cells. When the researchers used multiple techniques, including CRISPR-based gene editing, to eliminate the GAPB1L subunit from glioblastoma cells in laboratory cultures, the cells' growth dramatically slowed. The researchers then implanted patient-derived glioblastoma cells into mice and showed that while unedited cells grew aggressively and quickly proved fatal for the animals, cells edited to lack GAPB1L grew much more slowly and were less lethal.

Costello said the next step will be to identify small-molecule drugs that could have a similar effect as the gene editing used in the current experiments, which was performed in collaboration with co-authors Pablo Perez-Pinera, PhD, of the University of Illinois, Urbana-Champaign and CRISPR pioneer Jennifer Doudna, PhD, of UC Berkeley and the Gladstone Institutes in San Francisco, who is also an adjunct professor of cellular and molecular pharmacology at UCSF.

"In theory what we have now is a therapeutic target that is not TERT itself, but a key to the TERT switch that is not essential in normal cells," Costello said. "Now we have to design a therapeutic molecule that would do the same thing."

A San Francisco-based company called Telo Therapeutics, founded by Costello and former graduate student Robert Bell, PhD, who is also a co-author on the current study, is currently conducting small molecule screens to find such a molecule in partnership with pharmaceutical giant GlaxoSmithKline (GSK).

"It's gratifying that GSK is willing to invest their significant resources into this early-stage finding," Costello said. "To me, it really speaks to promise of this target for so many different human cancers."


Authors: Senior author Joseph Costello, PhD, is Karen Osney Brownstein Endowed Chair in Molecular Neuro-Oncology at UCSF, a professor in the Department of Neurological Surgery, and member of the UCSF Helen Diller Family Comprehensive Cancer Center. UCSF graduate student Andrew Mancini and former graduate student Ana Xavier-Magalhaes, PhD, were co-lead authors of the new study.

Other authors were Kien-Thiet Nguyen, Josie L. Hayes, PhD, Andrew M. McKinney, Chibo Hong, PhD, Lindsey E. Jones, Kyle M. Walsh, PhD, and Robert J.A. Bell, PhD, of UCSF; Alexandra M. Amen, PhD, of UCSF and UC Berkeley; Christof Fellmann, PhD, of UC Berkeley; Jennifer A. Doudna, PhD, of UC Berkeley, the Gladstone Institutes, and the Howard Hughes Medical Institute; Wendy S. Woods, Michael Gapinske, Jun S. Song, PhD, and Pablo Perez-Pinera, PhD, of the University of Illinois, Urbana-Champaign; and Bruno M. Costa, PhD, of the University of Minho in Braga, Portugal. Doudna is also an adjunct professor at UCSF and executive director of the UC Berkeley-UCSF Innovative Genomics Institute. Bell is now CEO at Telo Therapeutics.

Funding: This work was supported by the US National Institutes of Health (NIH) (NCI P50CA097257, NCI P01CA118816-06, T32 GM008568, T32 CA151022, NCI R01CA163336, NIGMS K99GM118909), the Dabbiere family, the Hana Jabsheh Research Initiative, the Sontag Foundation, and the Fundação para a Ciência e Tecnologia (SFRH/BD/88220/2012, IF/00601/2012).

Conflicts: Costello and Bell are co-founders of Telo Therapeutics Inc. and have ownership interest.

About UCSF: UC San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences; and a preeminent biomedical research enterprise. It also includes UCSF Health, which comprises three top-ranked hospitals - UCSF Medical Center and UCSF Benioff Children's Hospitals in San Francisco and Oakland - as well as Langley Porter Psychiatric Hospital and Clinics, UCSF Benioff Children's Physicians and the UCSF Faculty Practice. UCSF Health has affiliations with hospitals and health organizations throughout the Bay Area. UCSF faculty also provide all physician care at the public Zuckerberg San Francisco General Hospital and Trauma Center, and the SF VA Medical Center. The UCSF Fresno Medical Education Program is a major branch of the University of California, San Francisco's School of Medicine. Please visit

Follow UCSF | |

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.